VS38 Identifies Myeloma Cells with Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes with CD38 Detection for 4 to 6 Months

Elizabeth L. Courville, Sophia Yohe, Paula Shivers, Michael A. Linden

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'VS38 Identifies Myeloma Cells with Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes with CD38 Detection for 4 to 6 Months'. Together they form a unique fingerprint.

Medicine & Life Sciences